Behind-The-Counter Pseudoephedrine Strategy Builds In States
This article was originally published in The Tan Sheet
Executive Summary
State efforts to curtail methamphetamine production by limiting pseudoephedrine products to behind-the-counter sale likely will lend momentum to federal meth control bills
You may also be interested in...
Pseudoephedrine Behind-The-Counter Limits Loom In Patchwork Of State Bills
The U.S. Attorney General would be required to report to Congress on the effectiveness of state efforts to prevent methamphetamine precursor diversion under a House bill introduced March 2
CHPA Conference To Focus On Big Picture Healthcare Innovations
The Consumer Healthcare Products Association is using its Annual Executive Conference as a platform to discuss the future of broader healthcare trends
Pseudoephedrine Behind-The-Counter Sale Proposed In Congress; CHPA Balks
The efficacy of an Oklahoma law moving pseudoephedrine-containing products behind the counter must be evaluated over an extended follow-up period before extending legislation nationwide, according to industry trade group and DEA topsiders